Suzanne S Farid

List of Publications by Year
in descending order

101	3,069	212478	214428
papers	citations	28 h-index	50 g-index

109	109	109	2505
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Data integrity within the biopharmaceutical sector in the era of Industry 4.0. Biotechnology Journal, 2022, 17, e2100609.	1.8	13
2	Machine learning application in personalised lung cancer recurrence and survivability prediction. Computational and Structural Biotechnology Journal, 2022, 20, 1811-1820.	1.9	25
3	Lentiviral vector bioprocess economics for cell and gene therapy commercialization. Biochemical Engineering Journal, 2021, 167, 107868.	1.8	26
4	Process economics evaluation of cellâ€free synthesis for the commercial manufacture of antibody drug conjugates. Biotechnology Journal, 2021, 16, 2000238.	1.8	11
5	Machine learning reveals hidden stability code in protein native fluorescence. Computational and Structural Biotechnology Journal, 2021, 19, 2750-2760.	1.9	4
6	Advanced control strategies for bioprocess chromatography: Challenges and opportunities for intensified processes and next generation products. Journal of Chromatography A, 2021, 1639, 461914.	1.8	21
7	A common framework for integrated and continuous biomanufacturing. Biotechnology and Bioengineering, 2021, 118, 1735-1749.	1.7	39
8	Endâ€toâ€end continuous bioprocessing: Impact on facility design, cost of goods, and cost of development for monoclonal antibodies. Biotechnology and Bioengineering, 2021, 118, 3468-3485.	1.7	30
9	Decisional tool for cost of goods analysis of bioartificial liver devices for routine clinical use. Cytotherapy, 2021, 23, 683-693.	0.3	0
10	Gene therapy process change evaluation framework: Transient transfection and stable producer cell line comparison. Biochemical Engineering Journal, 2021, 176, 108202.	1.8	10
11	A decade in review: use of data analytics within the biopharmaceutical sector. Current Opinion in Chemical Engineering, 2021, 34, 100758.	3.8	20
12	Multivariate Data Analysis Methodology to Solve Data Challenges Related to Scaleâ€Up Model Validation and Missing Data on a Microâ€Bioreactor System. Biotechnology Journal, 2020, 15, 1800684.	1.8	17
13	Estimating capital investment and facility footprint in cell therapy facilities. Biochemical Engineering Journal, 2020, 155, 107439.	1.8	6
14	High-Throughput Raman Spectroscopy Combined with Innovate Data Analysis Workflow to Enhance Biopharmaceutical Process Development. Processes, 2020, 8, 1179.	1.3	22
15	Benchmarking biopharmaceutical process development and manufacturing cost contributions to R&D. MAbs, 2020, 12, 1754999.	2.6	41
16	Autologous CAR T-cell therapies supply chain: challenges and opportunities?. Cancer Gene Therapy, 2020, 27, 799-809.	2.2	46
17	How should we evaluate the cost-effectiveness of CAR T-cell therapies?. Health Policy and Technology, 2020, 9, 271-273.	1.3	1
18	Potential of Continuous Manufacturing for Liposomal Drug Products. Biotechnology Journal, 2019, 14, e1700740.	1.8	30

#	Article	IF	Citations
19	Modern day monitoring and control challenges outlined on an industrial-scale benchmark fermentation process. Computers and Chemical Engineering, 2019, 130, 106471.	2.0	29
20	Multi-objective biopharma capacity planning under uncertainty using a flexible genetic algorithm approach. Computers and Chemical Engineering, 2019, 128, 35-52.	2.0	7
21	High throughput process development workflow with advanced decision-support for antibody purification. Journal of Chromatography A, 2019, 1596, 104-116.	1.8	12
22	Dynamic scheduling of multi-product continuous biopharmaceutical facilities: A hyper-heuristic framework. Computers and Chemical Engineering, 2019, 125, 71-88.	2.0	13
23	Integrated Continuous Biomanufacturing: Industrialization on the Horizon. Biotechnology Journal, 2019, 14, e1800722.	1.8	13
24	Fast genetic algorithm approaches to solving discrete-time mixed integer linear programming problems of capacity planning and scheduling of biopharmaceutical manufacture. Computers and Chemical Engineering, 2019, 121, 212-223.	2.0	27
25	Onâ€Line Control of Glucose Concentration in Highâ€Yielding Mammalian Cell Cultures Enabled Through Oxygen Transfer Rate Measurements. Biotechnology Journal, 2018, 13, e1700607.	1.8	31
26	Technologies for large-scale umbilical cord-derived MSC expansion: Experimental performance and cost of goods analysis. Biochemical Engineering Journal, 2018, 135, 36-48.	1.8	55
27	Impact of allogeneic stem cell manufacturing decisions on cost of goods, process robustness and reimbursement. Biochemical Engineering Journal, 2018, 137, 132-151.	1.8	52
28	Cost-effective bioprocess design for the manufacture of allogeneic CAR-T cell therapies using a decisional tool with multi-attribute decision-making analysis. Biochemical Engineering Journal, 2018, 137, 192-204.	1.8	20
29	Bioprocesses for Cell Therapies. , 2018, , 899-930.		5
30	An automated laboratoryâ€scale methodology for the generation of sheared mammalian cell culture samples. Biotechnology Journal, 2017, 12, 1600730.	1.8	2
31	Predicting performance of constant flow depth filtration using constant pressure filtration data. Journal of Membrane Science, 2017, 531, 138-147.	4.1	28
32	Advanced multivariate data analysis to determine the root cause of trisulfide bond formation in a novel antibodyâ€“peptide fusion. Biotechnology and Bioengineering, 2017, 114, 2222-2234.	1.7	18
33	Integrated continuous bioprocessing: Economic, operational, and environmental feasibility for clinical and commercial antibody manufacture. Biotechnology Progress, 2017, 33, 854-866.	1.3	135
34	Multiâ€criteria manufacturability indices for ranking highâ€concentration monoclonal antibody formulations. Biotechnology and Bioengineering, 2017, 114, 2043-2056.	1.7	23
35	An integrated experimental and economic evaluation of cell therapy affinity purification technologies. Regenerative Medicine, 2017, 12, 397-417.	0.8	15
36	A roadmap for cost-of-goods planning to guide economic production of cell therapy products. Cytotherapy, 2017, 19, 1383-1391.	0.3	59

#	Article	IF	Citations
37	A new lot sizing and scheduling heuristic for multi-site biopharmaceutical production. Journal of Heuristics, 2017, 23, 231-256.	1.1	6
38	Continuous-Time Heuristic Model for Medium-Term Capacity Planning of a Multi-Suite, Multi-Product Biopharmaceutical Facility. Computer Aided Chemical Engineering, 2017, 40, 1303-1308.	0.3	1
39	Patient-specific hiPSC bioprocessing for drug screening: Bioprocess economics and optimisation. Biochemical Engineering Journal, 2016, 108, 84-97.	1.8	23
40	Integrated economic and experimental framework for screening of primary recovery technologies for high cell density CHO cultures. Biotechnology Journal, 2016, 11, 899-909.	1.8	10
41	Integrated Optimization of Upstream and Downstream Processing in Biopharmaceutical Manufacturing under Uncertainty: A Chance Constrained Programming Approach. Industrial & Engineering Chemistry Research, 2016, 55, 4599-4612.	1.8	23
42	Process change evaluation framework for allogeneic cell therapies: impact on drug development and commercialization. Regenerative Medicine, 2016, 11, 287-305.	0.8	17
43	A scaleâ€down mimic for mapping the process performance of centrifugation, depth and sterile filtration. Biotechnology and Bioengineering, 2016, 113, 1934-1941.	1.7	17
44	Industry 4.0: a vision for personalized medicine supply chains?. Cell & Gene Therapy Insights, 2016, 2, 263-270.	0.1	48
45	Manufacturability Indices for High-Concentration Monoclonal Antibody Formulations. Computer Aided Chemical Engineering, 2015, 37, 2147-2152.	0.3	3
46	Mathematical programming approaches for downstream processing optimisation of biopharmaceuticals. Chemical Engineering Research and Design, 2015, 94, 18-31.	2.7	16
47	Allogeneic cell therapy bioprocess economics and optimization: downstream processing decisions. Regenerative Medicine, 2015, 10, 591-609.	0.8	59
48	Human pluripotent stem cellâ€derived products: Advances towards robust, scalable and costâ€effective manufacturing strategies. Biotechnology Journal, 2015, 10, 83-95.	1.8	82
49	Representative mammalian cell culture test materials for assessment of primary recovery technologies: A rapid method with industrial applicability. Biotechnology Journal, 2015, 10, 162-170.	1.8	5
50	Multiobjective evolutionary optimization in antibody purification process design. Biochemical Engineering Journal, 2014, 91, 250-264.	1.8	13
51	Allogeneic cell therapy bioprocess economics and optimization: Singleâ€use cell expansion technologies. Biotechnology and Bioengineering, 2014, 111, 69-83.	1.7	151
52	Closedâ€loop optimization of chromatography column sizing strategies in biopharmaceutical manufacture. Journal of Chemical Technology and Biotechnology, 2014, 89, 1481-1490.	1.6	18
53	An Optimisation-based Approach for Biopharmaceutical Manufacturing. Computer Aided Chemical Engineering, 2014, 33, 1183-1188.	0.3	2
54	Optimising chromatography strategies of antibody purification processes by mixed integer fractional programming techniques. Computers and Chemical Engineering, 2014, 68, 151-164.	2.0	23

#	Article	IF	Citations
55	Data mining for rapid prediction of facility fit and debottlenecking of biomanufacturing facilities. Journal of Biotechnology, 2014, 179, 17-25.	1.9	24
56	Capacity planning for batch and perfusion bioprocesses across multiple biopharmaceutical facilities. Biotechnology Progress, 2014, 30, 594-606.	1.3	36
57	Tuning Evolutionary Multiobjective Optimization for Closed-Loop Estimation of Chromatographic Operating Conditions. Lecture Notes in Computer Science, 2014, , 741-750.	1.0	2
58	A Multiobjective Evolutionary Optimization Framework for Protein Purification Process Design. Lecture Notes in Computer Science, 2014, , 498-507.	1.0	1
59	Optimising the design and operation of semi-continuous affinity chromatography for clinical and commercial manufacture. Journal of Chromatography A, 2013, 1284, 17-27.	1.8	121
60	Fedâ€batch and perfusion culture processes: Economic, environmental, and operational feasibility under uncertainty. Biotechnology and Bioengineering, 2013, 110, 206-219.	1.7	240
61	Integration of stochastic simulation with multivariate analysis: Shortâ€term facility fit prediction. Biotechnology Progress, 2013, 29, 368-377.	1.3	11
62	Designing costâ€effective biopharmaceutical facilities using mixedâ€integer optimization. Biotechnology Progress, 2013, 29, 1472-1483.	1.3	21
63	Prediction of biopharmaceutical facility fit issues using decision tree analysis. Computer Aided Chemical Engineering, 2013, 32, 61-66.	0.3	9
64	Mixed integer optimisation of antibody purification processes. Computer Aided Chemical Engineering, 2013, 32, 157-162.	0.3	7
65	Production planning of batch and semi-continuous bioprocesses across multiple biopharmaceutical facilities. Computer Aided Chemical Engineering, 2012, 30, 377-381.	0.3	2
66	A multi-level meta-heuristic algorithm for the optimisation of antibody purification processes. Biochemical Engineering Journal, 2012, 69, 144-154.	1.8	28
67	Computer-Aided Design and Evaluation of Batch and Continuous Multi-Mode Biopharmaceutical Manufacturing Processes. Computer Aided Chemical Engineering, 2012, 30, 487-491.	0.3	1
68	Decisional tool to assess current and future process robustness in an antibody purification facility. Biotechnology Progress, 2012, 28, 1019-1028.	1.3	21
69	Efficient Discovery of Chromatography Equipment Sizing Strategies for Antibody Purification Processes Using Evolutionary Computing. Lecture Notes in Computer Science, 2012, , 468-477.	1.0	5
70	How implementation of Quality by Design and advances in Biochemical Engineering are enabling efficient bioprocess development and manufacture. Journal of Chemical Technology and Biotechnology, 2011, 86, 1125-1129.	1.6	23
71	Application of quality by design principles to the development and technology transfer of a major process improvement for the manufacture of a recombinant protein. Biotechnology Progress, 2011, 27, 1718-1729.	1.3	30
72	Designing multi-product biopharmaceutical facilities using evolutionary algorithms. Computer Aided Chemical Engineering, 2011, , 286-290.	0.3	3

#	Article	IF	Citations
73	Integration of stochastic simulation with advanced multivariate and visualisation analyses for rapid prediction of facility fit issues in biopharmaceutical processes. Computer Aided Chemical Engineering, 2011, , 1356-1360.	0.3	2
74	Windows of operation for bioreactor design for the controlled formation of tissueâ€engineered arteries. Biotechnology Progress, 2009, 25, 842-853.	1.3	3
75	Combinatorial Optimisation Algorithms for Strategic Biopharmaceutical Portfolio & Capacity Management. Computer Aided Chemical Engineering, 2009, 26, 1063-1068.	0.3	0
76	Dynamic Simulation Framework for Design of Lean Biopharmaceutical Manufacturing Operations. Computer Aided Chemical Engineering, 2009, 26, 1069-1073.	0.3	8
77	Application of a Decision-Support Tool to Assess Pooling Strategies in Perfusion Culture Processes under Uncertainty. Biotechnology Progress, 2008, 21, 1231-1242.	1.3	50
78	Corrections. Biotechnology Progress, 2008, 21, 320-320.	1.3	3
79	Decision-Support Tool for Assessing Biomanufacturing Strategies under Uncertainty: Stainless Steel versus Disposable Equipment for Clinical Trial Material Preparation. Biotechnology Progress, 2008, 21, 486-497.	1.3	101
80	Combining Multiple Quantitative and Qualitative Goals When Assessing Biomanufacturing Strategies under Uncertainty. Biotechnology Progress, 2008, 21, 1183-1191.	1.3	33
81	Strategic Biopharmaceutical Portfolio Development: An Analysis of Constraint-Induced Implications. Biotechnology Progress, 2008, 24, 698-713.	1.3	18
82	Stochastic Combinatorial Optimization Approach to Biopharmaceutical Portfolio Management. Industrial & Engineering Chemistry Research, 2008, 47, 8762-8774.	1.8	14
83	Modelling biopharmaceutical manufacture: Design and implementation of SimBiopharma. Computers and Chemical Engineering, 2007, 31, 1141-1158.	2.0	43
84	A multi-criteria decision-making framework for the selection of strategies for acquiring biopharmaceutical manufacturing capacity. Computers and Chemical Engineering, 2007, 31, 889-901.	2.0	25
85	Process economics of industrial monoclonal antibody manufacture. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2007, 848, 8-18.	1.2	318
86	Multiobjective Long-Term Planning of Biopharmaceutical Manufacturing Facilities. Biotechnology Progress, 2007, 23, 1383-1393.	1.3	22
87	Established Bioprocesses for Producing Antibodies as aÂBasis for Future Planning. Advances in Biochemical Engineering/Biotechnology, 2006, 101, 1-42.	0.6	39
88	Retrofit Decisions within the Biopharmaceutical Industry. Food and Bioproducts Processing, 2006, 84, 84-89.	1.8	4
89	A computer-aided approach to compare the production economics of fed-batch and perfusion culture under uncertainty. Biotechnology and Bioengineering, 2006, 93, 687-697.	1.7	78
90	Shear stress analysis of mammalian cell suspensions for prediction of industrial centrifugation and its verification. Biotechnology and Bioengineering, 2006, 95, 483-491.	1.7	102

#	Article	IF	Citations
91	Integrated approach to improving the value potential of biopharmaceutical R&D portfolios while mitigating risk. Journal of Chemical Technology and Biotechnology, 2006, 81, 1705-1714.	1.6	16
92	Medium term planning of biopharmaceutical manufacture under uncertainty. Computer Aided Chemical Engineering, 2006, 21, 2069-2074.	0.3	3
93	Medium Term Planning of Biopharmaceutical Manufacture with Uncertain Fermentation Titers. Biotechnology Progress, 2006, 22, 1630-1636.	1.3	13
94	Medium term planning of biopharmaceutical manufacture with uncertain fermentation titers. Biotechnology Progress, 2006, 22, 1630-6.	1.3	4
95	Modelling of the biopharmaceutical drug development pathway and portfolio management. Computers and Chemical Engineering, 2005, 29, 1357-1368.	2.0	37
96	A software tool to assist business-process decision-making in the biopharmaceutical industry. Biotechnology Progress, 2004, 20, 1096-1102.	1.3	17
97	A decisional-support tool to model the impact of regulatory compliance activities in the biomanufacturing industry. Computers and Chemical Engineering, 2004, 28, 727-735.	2.0	21
98	A tool for modelling the impact of regulatory compliance activities on the biomanufacturing industry. Computer Aided Chemical Engineering, 2003, , 1109-1114.	0.3	0
99	Decision-Support Tool for Risk Analysis in Biopharmaceutical Manufacture. IFAC Postprint Volumes IPPV / International Federation of Automatic Control, 2001, 34, 161-165.	0.4	0
100	A hierarchical framework for modelling biopharmaceutical manufacture to address process and business needs. Computer Aided Chemical Engineering, 2000, , 673-678.	0.3	0
101	A Tool for Modeling Strategic Decisions in Cell Culture Manufacturing. Biotechnology Progress, 2000, 16, 829-836.	1.3	33